BioWorld Asia

Sep. 17, 2008

View Archived Issues

Blocking Heat Shock Proteins Points to More Selective Drugs

Unibioscreen Gets Up to $31M in Cancer Drug Deal with Drais

NicOx Shows Positive Data From 2nd Naproxcinod Trial

Polyplus-transfection Develops New Class of Oligonucleotides

Biomarker Data Point to Target Patients for Transgene's Vaccine

CV Therapeutics Gets $70M Up Front in Ex-U.S. Ranexa Deal

Other News To Note

Cell Medica Begins Study of CMV Transplant Therapy

LONDON - Cell Medica Ltd. has treated the first patient in a Phase III trial of a cell therapy treatment for the prevention of cytomegalovirus (CMV) infection in immunocompromised bone marrow transplant patients. (BioWorld International) Read More

HemoCORM, Alfama Align in Carbon Monoxide Deal

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...